/

Clarity Pharmaceuticals Ltd

CLRPF PQ

CLRPF PQClarity Pharmaceuticals Ltd

OTC MARKETS

1.69

USD

+0.04

(+2.68%)

-0.06EPS Dil.

-28.17P/E

442.99MMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Held by Insiders

34.83%

Held by Institutions

8.03%

YTD Yield

247.96%

Capital Structure

FRC

•

in mil. unless spec.

Jun'22

Jun'23

ST Debt

premium

LT Borrowings

premium

LT Finance Leases

premium

Preferred Equity and Hybrid Capital

premium

Shares Outstanding

premium

Market Capitalization

premium

Working Capital

FRC

•

in mil. unless spec.

Jun'22

Jun'23

Total Current Assets

premium

Cash, Cash Equivalents & STI

premium

Accounts Receivable, Net

premium

Inventories

premium

Total Current Liabilities

premium

Payables & Accruals

premium

ST Debt

premium

Deferred Revenue

premium

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

premium

Net Income, GAAP

premium

Free Cash Flow

premium

Total Cash Common Dividend

premium

Total Equity

premium

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

premium

2023

- -

premium

- -

premium

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

premium

2023

- -

premium

- -

premium

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

premium

2023

- -

premium

- -

premium

Company Description

CEO: Dr. Colin David Biggin Ph.D.
Full Time Employees: 41
Sector: Healthcare
Industry: Biotechnology
Address: National Innovation Centre Sydney NSW Australia 2015
IPO Date: Aug 25, 2021
Website: www.claritypharmaceuticals.com
Business: Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Company News

Bloomberg
18 days ago
Nuclear Medicine Is Big Pharma’s New Target in Cancer Race

Company Description

CEO: Dr. Colin David Biggin Ph.D.
Full Time Employees: 41
Sector: Healthcare
Industry: Biotechnology
Address: National Innovation Centre Sydney NSW Australia 2015
IPO Date: Aug 25, 2021
Website: www.claritypharmaceuticals.com
Business: Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.